News
Pfizer CEO thinks pharma tariffs won’t be applied equally
For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an interview that there’s room for other products as more doctors become aware of the disease and patients get diagnosed earlier. Read more.
Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...
Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...
Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker ...
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...
The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...
After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...
Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...
Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...
Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...
Given the stock’s generous 7% yield, maybe junk bond investors should take a look.The venerable drug company, which also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback